Wall Street Sees 21% Upside for Rivian Despite R2 Pricing Disappointment

Photo of Thomas Richmond
By Thomas Richmond Published

Quick Read

  • Rivian (RIVN) delayed its $45,000 entry-level R2 SUV until 2027, with initial launch pricing at $57,990, causing the stock to fall 6.4% as the mass-market vehicle is critical to the company’s future growth and valuation thesis.

  • Rivian achieved its first full-year positive gross profit, signed a $1.25B Uber robotaxi deal that could deploy 50,000 R2-based vehicles starting 2028, and secured a $1B Volkswagen investment despite Q1 deliveries dropping 26.5% year over year.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Wall Street Sees 21% Upside for Rivian Despite R2 Pricing Disappointment

© Rivian

Rivian (NASDAQ:RIVN | RIVN Price Prediction) currently trades around $15, while Wall Street’s average price target sits at $18.16. That means analysts see roughly 21% upside for the stock today. Rivian designs and builds premium electric trucks, SUVs, and commercial vans, and is now betting its future on the R2 platform, a next-generation, lower-cost SUV designed for the mass market. Unlike Rivian’s current R1 vehicles, which are positioned as premium offerings, the R2 is meant to expand the company’s reach to a much broader customer base when deliveries begin in 2026. Wall Street has been watching closely because the company just posted its first full year of positive gross profit, signed a $1.25 billion robotaxi deal with Uber, and triggered a $1 billion Volkswagen investment after winter testing of their joint zonal architecture.

The R2 Pricing Surprise That Sent The Stock Lower

The selloff was driven by changes to the R2 rollout. Rivian originally targeted a $45,000 entry-level model, but that version is now delayed until 2027. The initial launch trim will instead start around $57,990, raising concerns about affordability and demand. The stock fell 6.4% on the news and dropped roughly 16% over the following month. CEO RJ Scaringe has called R2 the company’s “make-or-break product,” so any pricing slippage directly hits the thesis.

Operating data added pressure. Q1 deliveries fell 26.5% year over year to 8,141 vehicles, and the expiration of federal EV tax credits also reduced regulatory credit revenue from $299 million to $29 million in Q4, contributing to a sharp drop in automotive revenue. Insider activity hasn’t helped. Scaringe has sold stock in three separate transactions since March under a 10b5-1 plan, and CFO Claire McDonough sold 10,245 shares at $18.00 in late April.

Why The Bull Case Still Holds

Despite near-term pressure, analysts continue to focus on Rivian’s longer-term potential. Software and services revenue grew 109% year over year to $447 million, highlighting a higher-margin opportunity beyond vehicle sales. The company also has nearly $2 billion in remaining value tied to its joint venture with Volkswagen.

Partnerships remain central to the thesis. The Uber agreement could put up to 50,000 R2-based robotaxis on the road starting in 2028, while the VW collaboration provides both capital and validation of Rivian’s underlying technology.

The 26 analysts covering the stock are generally either bullish or neutral about the business:

  • Strong Buy: 4
  • Buy: 8
  • Hold: 8
  • Sell: 3
  • Strong Sell: 3

DA Davidson upgraded from Underperform to Neutral while keeping a $14 target, and Baird reaffirmed Outperform after the R2’s 335-mile EPA range certification. The thesis hinges on the next 18 months: R2 production ramp through 2026, RAP1 autonomy hardware launching in R2 by late 2026, and the Georgia facility funded partly by a DOE loan of up to $6.6 billion.

My Take: A High-Upside Story With Major Execution Risk

The bull case rests on Rivian delivering on the R2 platform. If production ramps successfully, partnerships continue to fund growth, and software revenue scales, the stock has a path back toward analyst targets and potentially higher. However, the bear case could easily play out with delays of the lower-cost R2 variant raising questions about cost structure, while continued sales declines and ongoing cash burn could force additional capital raises.

My view is that the upside is meaningful if Rivian executes, but the gap to analyst price targets is not large enough to ignore the risks. This is a stock that likely needs to prove the R2 story in real time before the next leg higher.

Photo of Thomas Richmond
About the Author Thomas Richmond →

Thomas Richmond is a financial writer and content strategist with 5+ years of experience covering stocks and financial markets. He has published over 250 articles focused on individual stock analysis, helping investors better understand business fundamentals, stock valuations, and long-term opportunities.

Thomas previously served as a Content Lead at TIKR, a stock research platform, where he helped scale the company’s blog to hundreds of articles per month and contributed to a weekly newsletter reaching more than 100,000 investors.

He specializes in breaking down complex companies into clear, actionable insights for everyday investors, with a focus on fundamentals-driven research.

His work has also been featured on platforms including Seeking Alpha and Sure Dividend.

Outside of work, Thomas enjoys weight lifting and soccer.

Continue Reading

Top Gaining Stocks

MU Vol: 26,371,095
COIN Vol: 5,446,913
EBAY Vol: 11,299,499
ORCL Vol: 19,460,093
MRNA Vol: 2,254,189

Top Losing Stocks

UPS Vol: 8,531,359
FDX Vol: 2,278,612
CHRW Vol: 1,615,740
NCLH Vol: 29,032,643